Evidence map›Paper›PMID 40513184›Full record

ReviewPharmacological reviews2025

Pharmaceutical perspectives on oligonucleotide therapeutics and delivery systems.

Dalton W Staller, Flobater I Gawargi, Sanjali S Panigrahi, Paras K Mishra, Ram I Mahato

Abstract readReview
In one paragraph

Review in Pharmacological reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dalton W StallerDepartment of Cellular & Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska.
Flobater I GawargiDepartment of Cellular & Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska.
Sanjali S PanigrahiDepartment of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska.
Paras K MishraDepartment of Cellular & Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska.
Ram I MahatoDepartment of Cellular & Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska; Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska. Electronic address: ram.mahato@unmc.edu.

Funding

Development and Preclinical Evaluation of Nanoformulations in Liver Fibrotic MiceR01DK135817 · NIDDK · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Ram I. Mahato, NATALIA ALEKSANDR OSNA · 2023 to 2026
$1.6M
Targeted Delivery of TFOs for Treatment of Liver FibrosisR01EB003922 · NIBIB · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI MAHATO, RAM I. · 2007 to 2010
$904k
Mechanism of metabolic remodeling in the diabetic heartR56HL156806 · NHLBI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI MISHRA, PARAS KUMAR · 2022 to 2022
$400k
NHLBI NIH HHS R56 HL156806NIBIB NIH HHS R01 EB003922NIDDK NIH HHS R01 DK135817
6 · The paper itself

Abstract

Gene therapy has a pivotal role in treating new diseases. In addition to the recent mRNA-based COVID-19 vaccines produced by Pfizer-BioNTech and Moderna against severe acute respiratory syndrome corona virus 2, several new gene therapies have recently been approved as effective treatments for fatal genetic disorders such as Duchenne's muscular dystrophy, familial transthyretin amyloidosis, hemophilia A, hemophilia B, spinal muscle atrophy, early cerebral autoleukodystrophy, and β-thalassemia. This review provides novel insights into RNA therapeutics focusing on endogenous RNA species, RNA structure and function, and chemical modifications that improve the stability and distribution of RNAs. Furthermore, it includes updated knowledge on clinically approved gene therapies rendering a comprehensive understanding of the biochemical basis and clinical application of gene therapies. SIGNIFICANCE STATEMENT: There have recently been significant advances in clinical translation of RNA therapeutics. This review discusses the diverse types of RNA species, RNA structure and function, backbone and chemical modifications to RNAs, and every RNA therapeutic approved for clinical use at the time of writing.

Indexed as

Drug Delivery SystemsGenetic TherapyOligonucleotidesAnimalsCOVID-19HumansOligonucleotides

Identifiers

PMID40513184
PMCPMC13095453

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.